Board of Directors
News and Events
Improve patient quality of life
Expedite the benchtop-to-bedside process
Scientific advancement through public- private partnerships
Focus on translational medicine
DMD, SMA, and ALS
Spinal cord injury
ReveraGen BioPharma partners with NIH's TRND program.
ReveraGen names Ed Connor as Interim CEO and Beth Burnside as Senior Vice President of Development & Operations.
International efforts to standardize pre-clinical experiments in the mdx mouse model of DMD.
© 2011 ReveraGen BioPharma, Inc. All rights reserved.
Follow us on
Terms and Conditions